STOCK TITAN

BSTG - BSTG STOCK NEWS

Welcome to our dedicated page for BSTG news (Ticker: BSTG), a resource for investors and traders seeking the latest updates and insights on BSTG stock.

Biostage, Inc. (OTCQB: BSTG) is a trailblazing biotechnology company at the forefront of developing bioengineered organ implants. These implants cater to critical needs in treating life-threatening conditions such as cancer, trauma, and congenital abnormalities, specifically targeting the esophagus, bronchus, and trachea. Central to Biostage's innovation is its proprietary Cellframe™ technology platform. This platform stimulates the body's innate signaling pathways and natural healing processes, fostering the regeneration and restoration of organ function.

The breakthrough Cellframe™ technology combines a synthetic scaffold with tissue engineering and cell biology to produce organ-specific Cellspan™ implants. These implants are strategically designed to facilitate in situ tissue regeneration by providing both stem cell-derived biological signals and three-dimensional structural support for cell growth and differentiation. A testament to its potential, recent large animal studies have shown promising results, notably in esophageal applications.

In an exciting development, Biostage has initiated its first clinical trial in the United States in collaboration with the Mayo Clinic, focusing on severe esophageal disease. This Phase 1, first-in-human study, approved by the FDA, aims to evaluate the safety and efficacy of the Cellspan™ esophageal implant in up to ten patients across five hospitals. The trial seeks to establish a continuous biological neo-conduit at three months post-implantation.

Biostage's commitment to advancing regenerative medicine is further emphasized by its robust intellectual property portfolio, which includes 13 issued U.S. patents, 2 issued in China, and 2 orphan-drug designations. These designations provide seven years of market exclusivity, reinforcing Biostage's competitive advantage.

The company's long-term vision is to provide next-generation solutions for organ restoration, eliminating the need for donor or animal transplants and avoiding the use of permanent artificial implants. This vision was notably realized in 2017 when Biostage successfully regenerated the esophagus in a patient with esophageal cancer, a milestone procedure that was later published in the Journal of Thoracic Oncology Clinical and Research Reports.

For the latest updates, Biostage regularly shares news on its website and through its social media channels, providing stakeholders with current advancements and financial performance.

Rhea-AI Summary
Harvard Apparatus Regenerative Technology, Inc. announced its financial results for Q2 2023, reporting a net loss of $2.6 million compared to $1.4 million in Q2 2022. The company activated its first clinical trial site with Mayo Clinic and contracted with IQVIA as the contract research organization. They also started a Consumer Health business in Hong Kong, planning to sell anti-aging supplements in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What does Biostage, Inc. specialize in?

Biostage specializes in developing bioengineered organ implants to address unmet medical needs in treating life-threatening conditions such as cancer, trauma, and congenital abnormalities.

What is the Cellframe™ technology?

Cellframe™ is Biostage’s proprietary technology platform designed to stimulate the body's natural healing processes to regenerate and restore organ function using a combination of synthetic scaffolds, tissue engineering, and cell biology.

What are Cellspan™ implants?

Cellspan™ implants are organ-specific implants created using the Cellframe™ technology. They are designed for in situ tissue regeneration, providing biological signals and structural support for cell growth and differentiation.

What recent advancements has Biostage made?

Biostage recently initiated its first clinical trial in the U.S. in collaboration with the Mayo Clinic, evaluating the safety and efficacy of Cellspan™ esophageal implants.

What is the goal of Biostage's current clinical trial?

The goal is to establish the safety and efficacy of the Cellspan™ esophageal implant in regenerating a continuous biological neo-conduit in patients with severe esophageal disease.

How does Biostage’s technology benefit patients?

Biostage's technology enables patients to regenerate their own organs, potentially eliminating the need for donor transplants, animal transplants, or permanent artificial implants.

What significant achievement did Biostage attain in 2017?

In 2017, Biostage achieved the world's first successful esophagus regeneration in a patient with esophageal cancer. The procedure was a significant milestone in the field of regenerative medicine.

How does Biostage ensure market exclusivity for its products?

Biostage holds 13 issued U.S. patents, 2 issued in China, and 2 orphan-drug designations, which provide up to seven years of market exclusivity in addition to patent protections.

Where can I find the latest news and updates about Biostage?

The latest news and updates about Biostage can be found on the company's official website and social media channels such as Twitter and LinkedIn.

How can I contact Biostage for investor relations?

For investor relations inquiries, you can contact Joseph Damasio, Chief Financial Officer, at 774-233-7330 or via email at jdamasio@biostage.com.

BSTG

OTC:BSTG

BSTG Rankings

BSTG Stock Data

63.85M
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing